Kristoffer Staal Rohrberg (Kristoffer S Rohrberg, Kristoffer Rohrberg)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Ejection Fraction

Small Cell Lung Cancer

Chronic Lymphocytic Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Solange Peters, Eric Angevin, Teresa Alonso Gordoa, Kristoffer Staal Rohrberg, Ignacio Melero Bermejo, Begona Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christiane Neumann, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umaña, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Solange Peters, Eric Angevin, Teresa Alonso Gordoa, Kristoffer Staal Rohrberg, Ignacio Melero Bermejo, Begona Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christiane Neumann, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umaña, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Neeltje Steeghs, Carlos Alberto Gomez Roca, Kristoffer Staal Rohrberg, Morten Mau Sorensen, Debbie G J Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero Bermejo
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neeltje Steeghs, Carlos Alberto Gomez Roca, Kristoffer Staal Rohrberg, Morten Mau Sorensen, Debbie G J Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero Bermejo
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neeltje Steeghs, Carlos Alberto Gomez Roca, Kristoffer Staal Rohrberg, Morten Mau Sorensen, Debbie G J Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero Bermejo
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Neeltje Steeghs, Carlos Alberto Gomez Roca, Kristoffer Staal Rohrberg, Morten Mau Sorensen, Debbie G J Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero Bermejo
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)
Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Staal Rohrberg, Sant P Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P Steinbach, Michael C Burger, Katharina Johanna Wenger, Ulrik N Lassen, Kamalesh K Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuss, Charles Cai, Eleni Lagkadinou, Michael Jeffers, Carol Peña, Ghazaleh Tabatabai
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Kristoffer Staal Rohrberg, Ulrik N Lassen
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Drugs 81 (4) (2021)
Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (4) (2018)